Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
Companies
» Company Monitoring Page for Bristol-Myers-Squibb
Company Monitoring Page for Bristol-Myers-Squibb
latest headlines for company on cafepharma
With Merck, J&J and BMS CEOs set to testify, Sanders releases scathing report on drug prices
Fierce Pharma
Tue, 02/6/24 - 11:33 pm
Tags:
Bernie Sanders
,
drug pricing
,
Merck
,
JNJ
,
Bristol Myers Squibb
,
Pharma CEOs
Top 40 Best-Selling Oncology Drugs in 2023 by 2022 Data
Xtalks
Mon, 02/5/24 - 10:17 am
Tags:
oncology
,
cancer
,
Keytruda
,
Revlimid
,
Opdivo
,
Imbruvica
,
Darzalex
,
Merck
,
Bristol Myers Squibb
,
AbbVie
,
Janssen
FDA sets date for high-profile CAR-T adcomm for Bristol's Abecma, J&J's Carvykti
Fierce Pharma
Sun, 02/4/24 - 12:39 pm
Tags:
Bristol Myers Squibb
,
Abecma
,
FRDA
,
CAR-T
,
JNJ
,
Carvykti
Bristol Myers CEO sees mid-decade transition, late decade growth
Reuters
Sun, 02/4/24 - 12:35 pm
Tags:
Bristol Myers Squibb
,
Pharma CEOs
,
Chris Boerner
BMS more likely to bet on bolt-ons after recent buying spree
Fierce Biotech
Fri, 02/2/24 - 11:59 am
Tags:
Bristol Myers Squibb
,
M&A
,
earnings
Cour gets $105M, pharma help to ‘reprogram’ autoimmune disease
BioPharma Dive
Tue, 01/30/24 - 11:10 am
Tags:
Cour Pharmaceuticals
,
funding
,
autoimmune disease
,
Roche
,
Pfizer
,
Bristol Myers Squibb
,
nanoparticles
BMS' subcutaneous Opdivo clears first phase 3 trial
Pharmaphorum
Mon, 01/29/24 - 11:05 am
Tags:
Bristol Myers Squibb
,
Opdivo
,
clinical trials
,
kidney cancer
,
subcutaneous Opdivo
BMS won out against other pharmas in bid for RayzeBio, just days after competing for Karuna
Fierce Biotech
Thu, 01/25/24 - 09:02 pm
Tags:
Bristol Myers Squibb
,
M&A
,
Rayze Bio
,
radiopharmaceuticals
Karuna, Cerevel might be just the start of psychiatry drug M&A
BioPharma Dive
Tue, 01/23/24 - 11:17 am
Tags:
M&A
,
Karuna Therapeutics
,
Cerevel Therapeutics
,
schizophrenia
,
AbbVie
,
Bristol Myers Squibb
Two more pharmas practice their Accent, invest in $75M series C round
Fierce Biotech
Tue, 01/23/24 - 10:47 am
Tags:
Accent Therapeutics
,
funding
,
RNA
,
Bristol Myers Squibb
,
JNJ
,
AbbVie
Another big pharma competed for Karuna, submitting all-cash offer day before BMS deal announcement
Fierce Biotech
Mon, 01/22/24 - 10:17 pm
Tags:
Karuna Therapeutics
,
Bristol Myers Squibb
,
M&A
Bristol Myers shows power of Opdivo-Yervoy combo in first-line colorectal cancer subset
Fierce Pharma
Sun, 01/21/24 - 05:09 pm
Tags:
Bristol Myers Squibb
,
colorectal cancer
,
Opdivo-Yervoy
Jilted by Bristol Myers, Ikena cuts headcount by 35% in retreat from drug discovery
Fierce Biotech
Fri, 01/19/24 - 09:28 am
Tags:
Ikena Oncology
,
Bristol Myers Squibb
,
layoffs
JPM24: Bristol Myers Squibb CEO Boerner emphasizes organic pipeline over recent M&A deals
Fierce Pharma
Tue, 01/9/24 - 10:49 am
Tags:
Bristol Myers Squibb
,
Pharma CEOs
,
Christopher Boerner
,
JPMHC 2024
Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference
Reuters
Fri, 01/5/24 - 11:25 am
Tags:
M&A
,
JPMHC 2024
,
AbbVie
,
AstraZeneca
,
Bristol Myers Squibb
,
Carmot Therapeutics
,
Eli Lilly
Biopharma Closes 2023 with Flurry of M&A Activity from AstraZeneca, BMS, Roche
BioSpace
Tue, 01/2/24 - 11:26 am
Tags:
M&A
,
AstraZeneca
,
Gracell Biotechnologies
,
Bristol Myers Squibb
,
Rayze Bio
,
Roche
BMS enters radiopharma race with $4.1B acquisition of RayzeBio just 3 months after biotech went public
Fierce Biotech
Wed, 12/27/23 - 11:15 pm
Tags:
Bristol Myers Squibb
,
RayzeBio
,
radiopharmaceuticals
,
M&A
Bristol Myers to acquire brain drug developer Karuna for $14B
BioPharma Dive
Fri, 12/22/23 - 09:44 am
Tags:
Bristol Myers Squibb
,
Karuna Therapeutics
,
schizophrenia
,
M&A
,
KarXT
Bristol Myers pays SystImmune $800M and adds to pharma’s ‘ADC’ deal spree
BioPharma Dive
Tue, 12/12/23 - 09:58 am
Tags:
Bristol Myers Squibb
,
SystImmune
,
antibody-drug conjugate
,
cancer
ASH: Abecma’s survival data show why FDA wanted expert meeting on the Bristol Myers cell therapy
Fierce Pharma
Mon, 12/11/23 - 10:55 pm
Tags:
ASH 2023
,
Abecma
,
FDA
,
CAR-T
,
Bristol Myers Squibb
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »
last 30 twitter posts
current feelings about your job
job rating
*
1 - I hate my job
2
3
4
5
6
7 - I love my job
Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
please tell us why
*
your industry
*
your job title (optional)
your company
*
published
N/A
published
not published
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
an umbrella protects you from: rain, sand, hunger
*
Fill in the blank.